keyword
MENU ▼
Read by QxMD icon Read
search

Peginterferon Alfa-2b

keyword
https://www.readbyqxmd.com/read/28748315/interferon-alpha-treatment-for-disease-control-in-metastatic-pheochromocytoma-paraganglioma-patients
#1
Julien Hadoux, Marie Terroir, Sophie Leboulleux, Frederic Deschamps, Abir Al Ghuzlan, Ségolène Hescot, Lambros Tselikas, Isabelle Borget, Caroline Caramella, Desirée Déandréis, Diane Goere, Thierry De Baere, Martin Schlumberger, Eric Baudin
Interferon-alpha (IFN-alpha) is recommended in neuroendocrine tumors (NET). Malignant pheochromocytoma and paragangliomas (MPPGLs) constitute a rare subgroup of NET with few treatment options. IFN-alpha efficacy in patients with MPPGLs was evaluated in a single-center retrospective study. Progression-free survival (PFS) was the primary endpoint according to RECIST 1.1 and/or PERCIST 1.0, and response rate, safety, and symptomatic efficacy were secondary endpoints. Fourteen patients received peginterferon alfa-2a (90 to 180 μg/week) or interferon alfa-2b (1...
July 26, 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28538872/melanoma-tumor-microenvironment-and-new-treatments
#2
Mara Huffenbaecher Giavina-Bianchi, Pedro Francisco Giavina-Bianchi, Cyro Festa
In the recent past years, many discoveries in the tumor microenvironment have led to changes in the management of melanoma and it is rising up hopes, specially, to those in advanced stages. FDA approved seven new drugs from 2011 to 2014. They are: Vemurafenib, Dabrafenib and Trametinib, kinases inhibitors used for patients that have BRAFV600E mutation; Ipilimumab (anti-CTLA4), Pembrolizumab (anti-PD-1) and Nivolumab (anti-PD-1), monoclonal antibodies that stimulate the immune system; and Peginterferon alfa-2b, an anti-proliferative cytokine used as adjuvant therapy...
March 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28469364/efficacy-and-safety-profile-of-boceprevir-or-telaprevir-based-triple-therapy-or-dual-peginterferon-alfa-2a-or-alfa-2b-plus-ribavirin-therapy-in-chronic-hepatitis-c-the-real-world-pegbase-observational-study
#3
Alessandra Mangia, Graham R Foster, Christoph P Berg, Manuela Curescu, Victor De Ledinghen, François Habersetzer, Spilios Manolakopoulos, Elisa Negri, George Papatheodoridis, Silke Ahlers, Marco Castillo, Georgios Bakalos, Stefan Mauss
BACKGROUND: The aim of the study was to determine the efficacy and safety of triple therapy with a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b plus ribavirin, and dual therapy (peginterferon alfa-2a or -2b plus ribavirin) in patients with chronic hepatitis C (CHC) in routine clinical practice. METHODS: PegBase was an international, prospective, observational study in which 4441 patients with CHC were enrolled in 27 countries...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28329061/pegylated-interferon-alfa-2b-add-on-treatment-in-hepatitis-b-virus-envelope-antigen-positive-chronic-hepatitis-b-patients-treated-with-nucleos-t-ide-analogue-a-randomized-controlled-trial-pegon
#4
RANDOMIZED CONTROLLED TRIAL
Heng Chi, Bettina E Hansen, Simin Guo, Ning Ping Zhang, Xun Qi, Liang Chen, Qing Guo, Pauline Arends, Ji-Yao Wang, Elke Verhey, Robert J de Knegt, Qing Xie, Harry L A Janssen
Background: We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy. Methods: This randomized trial included HBeAg-positive patients with compensated liver disease who were treated with entecavir/tenofovir for >12 months and had an HBV DNA load of <2000 IU/mL...
April 1, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27793166/hbsag-and-hbeag-in-the-prediction-of-a-clinical-response-to-peginterferon-%C3%AE-2b-therapy-in-chinese-hbeag-positive-patients
#5
RANDOMIZED CONTROLLED TRIAL
Song Yang, Huichun Xing, Yuming Wang, Jinlin Hou, Duande Luo, Qing Xie, Qin Ning, Hong Ren, Huiguo Ding, Jifang Sheng, Lai Wei, Shijun Chen, Xiaoling Fan, Wenxiang Huang, Chen Pan, Zhiliang Gao, Jiming Zhang, Boping Zhou, Guofeng Chen, Mobin Wan, Hong Tang, Guiqiang Wang, Yuxiu Yang, Dongping Xu, Peiling Dong, Qixin Wang, Jue Wang, Fernando A Bognar, Daozhen Xu, Jun Cheng
BACKGROUND: This study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of pegylated interferon alfa-2b therapy at 1.5 mcg/kg. METHODS: HBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48, and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response, SR] combined with HBV DNA level <2,000 IU/mL at week 72)...
October 28, 2016: Virology Journal
https://www.readbyqxmd.com/read/27710263/mechanisms-of-hyperbilirubinemia-during-peginterferon-lambda-1a-therapy-for-chronic-hepatitis-c-infection-a-retrospective-investigation
#6
Ricardo Zwirtes, Premkumar Narasimhan, Megan M Wind-Rotolo, Dong Xu, Matthew W Hruska, Narendra Kishnani, Elizabeth M Colston, Subasree Srinivasan
The phase 2b EMERGE study compared the efficacy/safety of peginterferon lambda-1a (Lambda) and peginterferon alfa-2a (Alfa), both with ribavirin (RBV), for treatment of chronic hepatitis C virus (HCV) infection. A key safety finding was a higher frequency of hyperbilirubinemia with Lambda/RBV versus Alfa/RBV. To characterize mechanisms of hyperbilirubinemia associated with Lambda/RBV, we conducted a retrospective analysis of safety data from the HCV genotype 1 and genotype 4 cohort of the EMERGE study. Subjects were randomized to once-weekly Lambda (120/180/240 μg) or Alfa (180 μg), with daily RBV, for 48 weeks...
October 6, 2016: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/27153246/safety-and-efficacy-of-faldaprevir-in-combination-with-pegylated-interferon-%C3%AE-2b-and-ribavirin-in-japanese-patients-with-genotype-1-chronic-hepatitis-c-virus-infection
#7
Shuhei Nishiguchi, Yasuhisa Urano, Keiko Suzaki, Atsushi Taniguchi, Joseph Scherer, Kristi L Berger, Anne-Marie Quinson, Jerry O Stern, Masao Omata
AIM: We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α-2b and ribavirin (PegIFNα-2b/RBV) in Japanese patients with HCV genotype-1 infection. METHODS: Treatment-naïve patients were randomized (1:1) to faldaprevir 120 mg q.d. for 12 or 24 weeks (response-guided therapy [RGT], n = 44), or faldaprevir 240 mg q.d. for 12 weeks (n = 43), each combined with PegIFNα-2b/RBV for 24 or 48 weeks (RGT)...
May 6, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27062488/efficacy-and-safety-of-telaprevir-with-pegylated-interferon-%C3%AE-2a-and-ribavirin-in-japanese-patients
#8
Hiromitsu Kumada, Fumitaka Suzuki, Naohiro Kamiya, Madori Orihashi, Yoshiyuki Nakayasu, Ichimaro Yamada
AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and relapsed patients compared to previous TVR-based triple therapy in Japan. METHODS: The study group included 35 treatment-naïve (median age, 55 years) and 19 relapsed (median age, 55 years) patients with genotype 1 hepatitis C virus infection. Patients received TVR (750 mg every 8 h) for 12 weeks, in combination with PEG-IFNα-2a and RBV...
May 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/26936417/vaniprevir-plus-peginterferon-alfa-2b-and-ribavirin-in-treatment-experienced-japanese-patients-with-hepatitis-c-virus-genotype-1-gt1b-infection-phase-3-studies
#9
RANDOMIZED CONTROLLED TRIAL
Hiromitsu Kumada, Satoshi Mochida, Fumitaka Suzuki, Kazuaki Chayama, Yoshiyasu Karino, Keisuke Nakamura, Go Fujimoto, Anita Y M Howe, Steve W Ludmerer, Niloufar Mobashery
BACKGROUND AND AIM: Vaniprevir is a macrocyclic hepatitis C virus (HCV) non-structural (NS)3/4A protease inhibitor. The objective of these phase 3 multicenter, open-label trials was to evaluate the safety and efficacy of vaniprevir + peginterferon alfa-2b + ribavirin (PR) in Japanese patients with HCV genotype (GT)1 infection who had previously failed treatment with interferon-based regimens. METHODS: Japanese patients with chronic HCV GT1 were enrolled...
October 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/26739688/peginterferon-lambda-for-the-treatment-of-hbeag-positive-chronic-hepatitis-b-a-randomized-phase-2b-study-lira-b
#10
RANDOMIZED CONTROLLED TRIAL
Henry L Y Chan, Sang Hoon Ahn, Ting-Tsung Chang, Cheng-Yuan Peng, David Wong, Carla S Coffin, Seng Gee Lim, Pei-Jer Chen, Harry L A Janssen, Patrick Marcellin, Lawrence Serfaty, Stefan Zeuzem, David Cohen, Linda Critelli, Dong Xu, Megan Wind-Rotolo, Elizabeth Cooney
BACKGROUND & AIMS: Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and hepatitis C virus (HCV); however, lambda has a more limited extra-hepatic receptor distribution. This phase 2b study (LIRA-B) evaluated lambda in patients with chronic HBV infection. METHODS: Adult HBeAg+ interferon-naive patients were randomized (1:1) to weekly lambda (180 μg) or peginterferon alfa-2a (alfa) for 48 weeks...
May 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/26403160/vaniprevir-plus-peginterferon-alfa-2b-and-ribavirin-in-treatment-naive-japanese-patients-with-hepatitis-c-virus-genotype-1-infection-a-randomized-phase-iii-study
#11
RANDOMIZED CONTROLLED TRIAL
Norio Hayashi, Makoto Nakamuta, Tetsuo Takehara, Hiromitsu Kumada, Akiko Takase, Anita Yee Mei Howe, Steven W Ludmerer, Niloufar Mobashery
BACKGROUND: Vaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This phase III study evaluated the safety and efficacy of vaniprevir in combination with peginterferon alfa-2b and ribavirin (PR) for 24 weeks compared with PR alone for 48 weeks in treatment-naive Japanese patients with HCV genotype 1 infection. METHODS: Treatment-naive Japanese patients with HCV genotype 1 infection were randomly assigned to receive vaniprevir (300 mg twice daily) plus PR for 12 weeks then PR alone for 12 weeks, vaniprevir (300 mg twice daily) plus PR for 24 weeks, or PR alone for 48 weeks...
April 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/26376344/peginterferon-lambda-1a-is-associated-with-a-low-incidence-of-autoimmune-thyroid-disease-in-chronic-hepatitis-c
#12
RANDOMIZED CONTROLLED TRIAL
Paul Fredlund, Jan Hillson, Todd Gray, Lynn Shemanski, Dessislava Dimitrova, Subasree Srinivasan
Peginterferon alfa (alfa) increases the risk of autoimmune disease. Peginterferon lambda-1a (Lambda) acts through a receptor with a more liver-specific distribution compared to the alfa receptor. In a phase-2b study, 525 treatment-naive patients with chronic hepatitis C virus (HCV) infection received ribavirin and Lambda interferon (120, 180, or 240 μg) or alfa interferon (180 μg) for 24 (genotypes 2 and 3) or 48 (genotypes 1 and 4) weeks. Retrospective analysis found that adverse events of MedDRA-coded thyroid dysfunction and abnormal levels of thyroid-stimulating hormone (TSH) were significantly more frequent with alfa versus Lambda (12% versus 2...
November 2015: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/26294237/simeprevir-and-sofosbuvir-for-treatment-of-hepatitis-c-infection
#13
REVIEW
Shelby Chopp, Rebecca Vanderwall, Amanda Hult, Michael Klepser
PURPOSE: The pharmacology, pharmacokinetics, efficacy, safety, costs, and place in therapy of simeprevir and sofosbuvir in the management of hepatitis C virus (HCV) infection are reviewed. SUMMARY: Sofosbuvir and simeprevir are classified as direct-acting agents because they target specific proteins essential to the replication of HCV. Phase III trials demonstrated that simeprevir in combination with peginterferon alfa and ribavirin was superior to placebo combined with peginterferon alfa and ribavirin in achieving a sustained virological response in both treatment-naive patients and patients who relapsed after treatment with peginterferon alfa-2a or alfa-2b and ribavirin...
September 1, 2015: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/26280154/polymorphisms-at-il28b-gene-as-predictors-of-viral-relapse-in-genotype-4-egyptian-hepatitis-c-patients
#14
Mona Abdelmonem Esmail, Noha A Hassuna, Khalda Sayed Amr, Eman Ramadan Ghazawy, Mohamed Abdel-Hamid
Chronic HCV is one of the commonest causes of chronic liver disease worldwide with about 15% of population infected in Egypt. Certain single nucleotide polymorphisms (SNPs) lying near the IL28B gene were found to affect the spontaneous clearance as well as treatment outcome of HCV. To examine the association between different IL28B variants and the relapse of HCV infection after combined therapy with ribavirin and pegylated interferon (pegIFN). Hundered HCV genotype four patients received 1.5 mg/kg/week peginterferon alfa-2b plus 800-1400 mg/d ribavirin (weight-adjusted) for 48 weeks...
March 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/26188762/perspectives-on-dual-hepatitis-b-and-c-infection-in-taiwan
#15
REVIEW
Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Tai-Chung Tseng, Jia-Horng Kao
Dual hepatitis C virus (HCV) and hepatitis B virus (HBV) infection is not rare in HBV or HCV endemic areas, and can be found in populations at risk of parenteral viral transmission. Clinical observatory studies suggest a higher risk of liver disease progression in patients with dual HCV/HBV infection than in HBV or HCV monoinfected patients. Recent trials confirmed that combination therapy of peginterferon alfa-2a or alfa-2b and ribavirin was effective and safe in dually infected patients with positive HCV RNA...
May 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/26188135/a-treatment-algorithm-for-the-management-of-chronic-hepatitis-b-virus-infection-in-the-united-states-2015-update
#16
REVIEW
Paul Martin, Daryl T-Y Lau, Mindie H Nguyen, Harry L A Janssen, Douglas T Dieterich, Marion G Peters, Ira M Jacobson
Chronic hepatitis B (CHB) continues to be an important public health problem worldwide, including in the United States. An algorithm for managing CHB was developed by a panel of United States hepatologists in 2004 and subsequently updated in 2006 and 2008. Since 2008, additional data on long-term safety and efficacy of licensed therapies have become available and have better defined therapeutic options for CHB. The evidence indicates that potent antiviral therapy can lead to regression of extensive fibrosis or even cirrhosis, thus potentially altering the natural history of CHB...
November 2015: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/26171394/novel-approaches-to-treatment-of-advanced-melanoma-a-review-on-targeted-therapy-and-immunotherapy
#17
REVIEW
Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski
The incidence of malignant melanoma is increasing. The majority of patients are diagnosed in early stages when the disease is highly curable. However, the more advanced or metastatic cases have always been a challenge for clinicians. The poor prognosis for patients with melanoma is now changing as numerous of promising approaches have appeared recently. The discovery of aberrations of pathways responsible for intracellular signal transduction allowed us to introduce agents specifically targeting the mutated cascades...
2015: BioMed Research International
https://www.readbyqxmd.com/read/25826356/impairment-of-type-i-but-not-type-iii-ifn-signaling-by-hepatitis-c-virus-infection-influences-antiviral-responses-in-primary-human-hepatocytes
#18
Jacques Friborg, Petra Ross-Macdonald, Jian Cao, Ryan Willard, Baiqing Lin, Betsy Eggers, Fiona McPhee
Peginterferon lambda-1a (Lambda), a type III interferon (IFN), acts through a unique receptor complex with limited cellular expression outside the liver which may result in a differentiated tolerability profile compared to peginterferon alfa (alfa). In Phase 2b clinical studies, Lambda administered in combination with ribavirin (RBV) was efficacious in patients with hepatitis C virus (HCV) infection representing genotypes 1 through 4, and was associated with more rapid declines in HCV RNA compared to alfa plus RBV...
2015: PloS One
https://www.readbyqxmd.com/read/25771464/responses-to-peginterferon-alfa-2a-vs-alfa-2b-plus-ribavirin-in-a-mexican-population-with-chronic-hepatitis-c
#19
COMPARATIVE STUDY
Jorge Luis Sandoval-Ramirez, José Antonio Mata-Marín, Gloria Huerta García, Jesús Enrique Gaytán-Martínez
INTRODUCTION: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in low-income countries, including Mexico. Two types of peginterferon are available (peginterferon alfa-2a and peginterferon alfa-2b), and both are recommended for the treatment of HCV, although there is controversy over which treatment option is most effective...
March 15, 2015: Journal of Infection in Developing Countries
https://www.readbyqxmd.com/read/25565777/comparison-of-peginterferon-alfa-2a-and-alfa-2b-for-treatment-of-patients-with-chronic-hepatitis-c-a-retrospective-study-using-the-japanese-interferon-database
#20
COMPARATIVE STUDY
Izumi Sato, Takuro Shimbo, Yohei Kawasaki, Naohiko Masaki
PURPOSE: We aimed to compare the rates of sustained virologic response (SVR) achieved with peginterferon (PEG-IFN) alfa-2a and alfa-2b in combination with ribavinin (RBV) for chronic hepatitis C, using a large database of hepatitis cases to improve the generalizability of these results. METHODS: We identified patients with chronic hepatitis C who were treated with PEG-IFN alfa-2a or alfa-2b and RBV, from the Japanese Interferon Database, between December 2009 and April 2013...
2015: Drug Design, Development and Therapy
keyword
keyword
10966
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"